QuidelOrtho Corporation (QDEL)

Over the past six months, QuidelOrtho's stock has experienced several notable events. In Q1 2025, the company reported a decrease in total revenue due to lower COVID-19 and Donor Screening revenue, but non-respiratory revenue showed growth, and adjusted diluted EPS exceeded the prior year period. In Q2 2025, the company reported an increase in adjusted diluted EPS year-over-year, surpassing analyst expectations, despite a decrease in total revenue due to lower COVID-19 testing and the wind-down of donor screening. The stock closed down following the announcement, reflecting mixed investor sentiment. QuidelOrtho received FDA approval for its Micro Typing Systems (MTS) DAT Card, leading to a stock jump. The stock has shown volatility, with a rise over the last six months, but a decrease over the last year.

QuidelOrtho's products and services exhibit demand seasonality, particularly in its respiratory diagnostics portfolio. The second quarter (Q2) is typically the lowest revenue quarter of the year due to seasonally low viral prevalence, especially in North America. Historically, the demand for influenza tests has shown seasonal spikes. The company's business is diversified across various segments, including Labs, Immunohematology, Point of Care, Molecular Diagnostics, and Donor Screening, which may have varying seasonal patterns.

QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products sold worldwide, specializing in in vitro diagnostics. The company operates within the Medical sector, specifically in the In Vitro & In Vivo Diagnostic Substances and Medical Products industries. QuidelOrtho develops, manufactures, and markets a diverse portfolio of diagnostic solutions, including rapid diagnostic tests, molecular diagnostics, immunoassay systems, and specialized diagnostic solutions. Its major product categories include visually-read lateral flow tests, Direct Fluorescent Antibodies (DFA), micro-titer production, fluorescent immunoassay products, molecular diagnostic products, immunodiagnostics, clinical chemistry, integrated testing systems, immunodiagnostic donor screening systems and services, and pre-transfusion testing.

QuidelOrtho Corporation has a global geographic footprint, with a presence in North America, Europe, the Middle East, Africa (EMEA), China, and other international countries. North America is the dominant market, generating the majority of its revenue. The company provides service and support in over 130 countries and territories.

In the past year, QuidelOrtho's brand reputation has been positively influenced by its continued innovation and product approvals. The FDA approval of the Micro Typing Systems (MTS) DAT Card and its showcasing at the AABB 2025 Annual Meeting underscore the company's leadership in transfusion medicine. The launch of the QUICKVUE Influenza + SARS Test highlights the company's focus on expanding its point-of-care offerings. The company has emphasized strong execution on cost-saving initiatives, driving improved margins and profitability. The company has faced challenges from persistent declines in COVID-related revenues, which has been a key earnings risk.

QuidelOrtho Corporation has a mixed ownership structure, primarily held by institutional investors. Institutional investors hold a significant portion of the company's shares. Major institutional owners include T. Rowe Price Investment Management Inc., Blackrock Inc., and Vanguard Group Inc. Individual investors represent a smaller portion of the stock. Insiders own a small percentage of the company, with Jack W. Schuler being the largest individual shareholder.